Hims & Hers (NYSE: HIMS) Health stock experienced a dramatic surge in after-hours trading on Friday, transforming what had been a subdued regular session into one of the most explosive moves of the day.
The shares closed the regular trading session at $15.74, a decline of about 0.88% amid lingering investor concerns over regulatory pressures on compounded weight-loss medications and broader market caution. However, in after-hours trading, HIMS stock jumped 39% to $22.
The rapid after-hours surge quickly drew the attention of traders and analysts. The rally was driven by a key development in the company’s ongoing dispute with pharmaceutical giant Novo Nordisk (NYSE: NVO).
Reports indicated the two firms had resolved a legal conflict that escalated earlier this year. Tensions had arisen over Hims & Hers offering compounded alternatives to Novo Nordisk’s branded obesity drugs, including Wegovy, which triggered lawsuits, patent challenges, and regulatory scrutiny.
Those issues had weighed heavily on investor sentiment, contributing to significant declines in the stock throughout 2026 as uncertainties mounted over the future of compounded GLP-1 therapies.
Under the emerging partnership, Novo Nordisk plans to make its authentic, FDA-approved weight-loss medications available directly through the Hims & Hers platform.
The collaboration effectively ends the prior feud and positions Hims & Hers to benefit from branded product sales rather than relying solely on compounded versions that faced legal and regulatory headwinds.
HIMS stock new opportunities
The arrangement opens new revenue opportunities for the telehealth provider while alleviating a key overhang that had pressured the stock for months.
Market participants viewed the news as a significant positive shift, removing a major risk factor and potentially enhancing long-term growth prospects in the booming obesity treatment market.
The announcement, expected to be formalized as early as Monday, sparked immediate enthusiasm among retail and institutional investors.
After-hours trading volume surged as the news spread across financial outlets and social platforms, boosting momentum. Shares of Novo Nordisk also rose modestly in extended trading, reflecting the perceived mutual benefits of the partnership and expanded distribution.
The rally followed earlier weakness in Hims & Hers stock, which had faced sharp pullbacks linked to FDA scrutiny of compounded drugs, patent litigation, and softer forward guidance after strong prior-year results.
The partnership news quickly shifted sentiment, highlighting the stock’s sensitivity to developments in the weight-loss market and its potential for rapid repricing on positive catalysts.
